01:19:09 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Stockholm
Hansa Biopharma är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av immunmodulerande enzymer. Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Övriga projekt fokuserar på utveckling av nya antikroppsmodulerande enzymer samt HBP-analys.


2021-10-21 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-14 Ordinarie utdelning HNSA 0.00 SEK
2021-05-12 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-06-24 Ordinarie utdelning HNSA 0.00 SEK
2020-06-23 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-10-31 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning HNSA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-07-19 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning HNSA 0.00 SEK
2018-05-29 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-12-22 Extra Bolagsstämma 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-07-20 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning HNSA 0.00 SEK
2017-05-23 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-21 Extra Bolagsstämma 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-07-21 Kvartalsrapport 2016-Q2
2016-05-11 Årsstämma 2016
2016-04-28 Ordinarie utdelning HNSA 0.00 SEK
2016-04-27 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-28 Kvartalsrapport 2015-Q3
2015-08-25 Kvartalsrapport 2015-Q2
2015-04-17 Ordinarie utdelning HNSA 0.00 SEK
2015-04-16 Årsstämma 2015
2015-04-16 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-07-25 Kvartalsrapport 2014-Q2
2014-06-04 Ordinarie utdelning HNSA 0.00 SEK
2014-06-03 Årsstämma 2014
2014-03-05 Extra Bolagsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-07-25 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning HNSA 0.00 SEK
2013-05-06 Årsstämma 2013
2013-02-07 Bokslutskommuniké 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-07-26 Kvartalsrapport 2012-Q2
2012-05-14 Årsstämma 2012
2012-02-09 Bokslutskommuniké 2011
2012-01-09 Extra Bolagsstämma 2011
2011-07-28 Kvartalsrapport 2011-Q2
2011-05-12 Årsstämma 2011
2011-05-06 Ordinarie utdelning HNSA 0.00 SEK
2010-04-30 Ordinarie utdelning HNSA 0.00 SEK
2010-02-10 Bokslutskommuniké 2009
2009-07-30 Kvartalsrapport 2009-Q1
2009-05-12 Kvartalsrapport 2009-Q2
2009-04-30 Ordinarie utdelning HNSA 0.00 SEK
2009-04-29 Årsstämma 1
2020-09-01 19:45:00
  • Idefirix recently granted formal approval by the EU Commission; First treatments expected in select countries in Q4 2020 in the EU 
  • Updating clinical timelines for ongoing and planned imlifidase trials due to continued impact from the COVID-19 pandemic 
  • High-level data read-out from the investigator initiated phase 2 study in anti-GBM expected in Q3, 2020, as previously guided

Lund, Sweden September 1, 2020. Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced updated guidance regarding its ongong and planned clinical trial program ahead of Management's participation at upcoming investor conferences in September.

Following the conditional approval recently granted by the EU Commission for Idefirix™ (imlifidase) in highly sensitized kidney transplant patients in the European Union, Hansa Biopharma expects the first treatments with Idefirix to be available to patients in select European countries during the fourth quarter 2020, as communicated earlier. 

As part of the conditional approval, a post-approval study will be initiated following the market authorization. The post-approval study is expected to commence in the second half of 2021 following ongoing site selection and alignment on country specific requirements. The transplantation centers participating in the study will embark on a mutual learning experience, and the post-approval study will run in parallel with the Company's commercial roll-out activities. 

The proposed study protocol for a randomised controlled trial (RCT) targeting highly-sensitized kidney patients in the US was submitted to the US Food and Drug Administration (FDA) in June, 2020. Discussions are currently ongoing with the FDA and, once the final protocol has been agreed upon, Hansa Biopharma will proceed to set up centers in the US and start to enroll patients.

Given the continued impact of the COVID-19 pandemic in the US affecting patient enrollment, and the timeline for finalization of the study protocol, Hansa Biopharma now expects recruitment of the first patient to be in the first half of 2021 (previously Q4 2020). Completion of enrollment is still expected to be in 2022 with a potential Biologics License Application (BLA) submission by 2023 under the accelerated approval path.

In the investigator initiated Phase 2 trial in anti-glomerular basement membrane (anti-GBM) disease, the last patient last visit took place in July and the Company expects to report high level data from this study during the third quarter of 2020, as previously guided. Anti-GBM is the first IgG mediated disease outside transplantation, where imlifidase is being investigated to potentially stop an immunologic attack.

Due to the widespread impact from the COVID-19 pandemic, the enrollment in the phase 2 programs in Guillain Barré Syndrom (GBS) and Antibody-mediated kidney transplant rejection (AMR) were temporarily halted for the past months. Hansa Biopharma expects to reinitiate enrollment of these studies in Q4 2020 under a risk-based, site-by-site approach. As a consequence, enrollment in the AMR study is now expected to be completed in the second half of 2021 (previously H1 2021). Enrollment in the GBS study is still expected to be completed in the second half of 2021, as previously guided. High-level data readout for both studies are now expected in the second half of 2022. 

Upcoming milestones and news flow
Q3 2020     Anti-GBM Phase 2 study: High-level data read out 
Q4 2020     Kidney transplantation EU: Commercial launch 
H1 2021     Kidney transplantation US: First patient dosed 
H1 2021     NiceR candidate: Completion of GMP process and IND-enabling tox studies
H2 2021     AMR Phase 2 study: Complete enrollment 
H2 2021     GBS Phase 2 study: Complete enrollment 
H2 2022     AMR Phase 2 study: Data read out 
H2 2022     GBS Phase 2 study: Data read out
2022           Kidney transplantation US: Complete enrollment
2023           Kidney transplantation US: 12 months follow-up completed 
2023           Kidney transplantation US: BLA submission

Disclaimer regarding the ongoing COVID-19 pandemic: Clinical trials are being impacted by the COVID-19 Pandemic. Challenges may arise, for example, from self-isolation, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with COVID-19. These challenges may lead to difficulties in meeting recruitment as well as protocol-specified procedures, including administration or use of the investigational product or adhering to protocol-mandated visits and laboratory/diagnostic testing.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR).